Results 101 to 110 of about 1,554,946 (301)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

THE STUDY OF IMMUNOTOXIC PROPERTIES OF AVERSECT FORTE AND AVERSECT COMBI

open access: yesРоссийский паразитологический журнал, 2016
Objective of research:  Determination of possible immunotoxic properties of Aversect  Forte (Ivermectin + Abamectin) and Aversect Combi (Ivermectin + Aversectin С).
M. V. Semenova, K. G. Kurochkina
doaj  

Effect of leukocyte-reduced platelet transfusion on the production of HLA antibodies in patients

open access: yesZhongguo shuxue zazhi
[Objective] To investigate the factors associated with HLA antibody formation in patients undergoing platelet transfusion and to evaluate the intervention effect of leukocyte depletion technology.
LI Jixin, LI Shaowen
doaj   +1 more source

Recombinant Vgr-1/BMP-6-expressing tumors induce fibrosis and endochondral bone formation in vivo. [PDF]

open access: yes, 1994
Members of the TGF-beta superfamily appear to modulate mesenchymal differentiation, including the processes of cartilage and bone formation. Nothing is yet known about the function of the TGF-beta-related factor vgr-1, also called bone morphogenetic ...
Derynck, R   +5 more
core  

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Antisperm antibody formation following Vasectomy

open access: yesJournal of Family and Reproductive Health, 2007
Objective: Seeking for fertility after previous vasectomy is increasing. Vasectomy may break the blood testis barrier and in this way the level of antisperm antibody increases.
Mohammad Reza Nowroozi   +4 more
doaj  

Progressive Upregulation of Oxidative Metabolism Facilitates Plasmablast Differentiation to a T-Independent Antigen

open access: yesCell Reports, 2018
Summary: Transitioning from a metabolically quiescent naive B cell to an antibody-secreting plasmablast requires division-dependent cellular differentiation.
Madeline J. Price   +3 more
doaj   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

open access: yesMolecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge   +17 more
wiley   +1 more source

Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion

open access: yesFrontiers in Immunology, 2018
Red blood cell (RBC) alloimmunization represents a significant immunological challenge for some patients. While a variety of immune constituents likely contribute to the initiation and orchestration of alloantibodies to RBC antigens, identification of ...
Seema R. Patel   +15 more
doaj   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy